Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Open-label, multicenter, multinational, interventional Clinical Trial to assess Efficacy and Safety of the extemporaneous combination of Nebivolol and Ramipril in hypertensive patients - ARTEMISIA study

    Summary
    EudraCT number
    2022-003060-25
    Trial protocol
    HU   BG  
    Global end of trial date
    19 Feb 2024

    Results information
    Results version number
    v1(current)
    This version publication date
    20 Feb 2025
    First version publication date
    20 Feb 2025
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    MEIN/22/NeRam-Hyp/001
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT06104423
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Menarini International Operation Luxembourg SA
    Sponsor organisation address
    1, Avenue de la Gare, Luxembourg L-1611, Luxembourg, Luxembourg,
    Public contact
    Simone Baldini, MD, Global Clin Man, A. MENARINI I.F.R SrL, +39 055 56809740, sbaldini@menarini.it
    Scientific contact
    Simone Baldini, MD, Global Clin Man, A. MENARINI I.F.R SrL, +39 055 56809740, sbaldini@menarini.it
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    29 Aug 2024
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    19 Feb 2024
    Global end of trial reached?
    Yes
    Global end of trial date
    19 Feb 2024
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To assess the antihypertensive efficacy of the extemporaneous combination of Nebivolol (NEB) 5 mg with Ramipril (RAM) 2.5 mg, 5 mg or 10 mg in lowering sitting Systolic blood pressure (SBP) between Visit 2 (Week 0) and Visit 5 (Week 12) in patients with uncontrolled blood pressure (BP) previously treated with NEB 5 mg or RAM 5 mg monotherapies for at least 30 days. For the purpose of this study, uncontrolled BP is defined as sitting Systolic blood pressure (SBP)/Diastolic blood pressure (DBP): • ≥ 130/80 mmHg in patients < 65 years old • ≥ 140/80 mmHg in patients ≥ 65 years old
    Protection of trial subjects
    This study was performed in compliance with International Council for Harmonisation (ICH) Good Clinical Practices (GCP), including the archiving of essential documents as well as the ethical principles of the Declaration of Helsinki.
    Background therapy
    All Patients are in therapy with anti hypertensive monotherapy treatment either with Beta blockers (BBs) (NEB 5 mg or any dose if other BB) or Angiotensin-converting enzyme inhibitors (ACE-i) (RAM 5 mg or any dose if other ACE-i) for at least 30 days before Visit 1 (screening)
    Evidence for comparator
    -
    Actual start date of recruitment
    02 Oct 2023
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Poland: 52
    Country: Number of subjects enrolled
    Bulgaria: 213
    Country: Number of subjects enrolled
    Hungary: 1
    Worldwide total number of subjects
    266
    EEA total number of subjects
    266
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    202
    From 65 to 84 years
    64
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Study started 02Oct2023 and terminated 19Feb2024. 270 patients (pts) were screened of which 266 pts entered the Run-In phase and were assigned monotherapy with NEB 5mg or RAM 5mg; 4 pts were screen failures. Out of these 266 pts, 11 pts were dropped during Run-In. 255 pts completed the trial (Run-In and combination therapy phase)

    Pre-assignment
    Screening details
    270 patients (pts) male and female uncontrolled hypertensive patients ≥ 18 years of age on monotherapy either with ACE-i or BBs since at least 1 month and with mean sitting SBP ≥ 140 mmHg and ≤ 179 mmHg and / or mean sitting DBP ≥ 90 mmHg and ≤ 109 mmHg, were screened.

    Period 1
    Period 1 title
    Run-In Period
    Is this the baseline period?
    No
    Allocation method
    Non-randomised - controlled
    Blinding used
    Not blinded
    Blinding implementation details
    Open- label study, not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Nebivolol 5 mg
    Arm description
    Eligible patients entered a 4 week run-in period on the same day of the screening visit (Visit 1, Week -4). Patients previously receiving Neb 5 mg continued the same treatment, while patients receiving any other BBs were switched to Neb 5 mg
    Arm type
    Active comparator

    Investigational medicinal product name
    Nebivolol 5 mg
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    1 tablet of study drug was administered with a glass of water once daily

    Arm title
    Ramipril 5 mg
    Arm description
    Eligible patients entered a 4 week run-in period on the same day of the screening visit (Visit 1, Week -4). Patients previously receiving RAM 5 mg continued the same treatment, while patients receiving any other ACE-i were switched to RAM 5 mg
    Arm type
    Active comparator

    Investigational medicinal product name
    Ramipril 5mg
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    1 tablet of study drug was administered with a glass of water once daily

    Number of subjects in period 1
    Nebivolol 5 mg Ramipril 5 mg
    Started
    128
    138
    Completed
    124
    131
    Not completed
    4
    7
         Not compliant with eligibility criteria
    3
    6
         Lab abnormal results
    1
    1
    Period 2
    Period 2 title
    Assessment
    Is this the baseline period?
    Yes [1]
    Allocation method
    Non-randomised - controlled
    Blinding used
    Not blinded
    Blinding implementation details
    Not blinded

    Arms
    Arm title
    Combination Therapy Neb 5mg/ Ram 2.5 or 5 or 10 mg
    Arm description
    Visit2 (V2) Week0 (W0): Patients (pts) having uncontrolled BP (BP≥130/80mmHg in pt<65y old/BP≥140/80mmHg in pt≥65y old) were assigned to the extemporaneous combination of NEB5mg and RAM2.5mg. V3 W4: After 4 Weeks ± 2 days controlled pt (BP<130/80mmHg in pt<65y old/ BP<140/80mmHg in pt ≥65y old) continued the same combination of V2 while for pt with uncontrolled BP the RAM dose was up-titrated to 5mg and the pt received the combination NEB/RAM 5/5mg for next 4 weeks. V4 W8: After 4 Weeks ± 2 days controlled pt continued the same combination of V3 for next 4 weeks ± 2 days till V5 (W12). Pt with uncontrolled BP: on NEB/RAM 5/2.5mg were up-titrated to NEB/RAM 5/5mg; on NEB/RAM 5/5mg were up-titrated to NEB/RAM 5/10mg for next 4 weeks ± 2 days till V5. To correctly evaluate additional effect of the combination therapy, the number of pts with uncontrolled BP needed to be balanced at V2 (max 5% difference). Weekly evaluations were performed to maintain a 1:1 during period 2.
    Arm type
    Experimental

    Investigational medicinal product name
    Nebivolol 5 mg
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    1 tablet of study medication was administered with a glass of water once daily

    Investigational medicinal product name
    Ramipril 2.5/5/10mg
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    1 tablet of study medication was administered with a glass of water once daily

    Notes
    [1] - Period 1 is not the baseline period. It is expected that period 1 will be the baseline period.
    Justification: Period 1 is the Run-in period. The objective of the study is to evaluate the effectiveness and safety of the combination therapy (Nebivolol/Ramipril) versus the monotherapy. Hence the baseline period starts on Period 2 (Assessment), with the assessment of blood pressure after the run-in period and the intake of the combination therapy.
    Number of subjects in period 2 [2]
    Combination Therapy Neb 5mg/ Ram 2.5 or 5 or 10 mg
    Started
    255
    Completed
    255
    Notes
    [2] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
    Justification: 270 patients are enrolled patients that are included in the study and start the Run-in period (Period 1). Period 1 is not the baseline period. The baseline period is Period 2 (Assessment) where patients start to take the combination therapy NEB 5 mg/RAM 2.5mg.

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Combination Therapy Neb 5mg/ Ram 2.5 or 5 or 10 mg
    Reporting group description
    Visit2 (V2) Week0 (W0): Patients (pts) having uncontrolled BP (BP≥130/80mmHg in pt<65y old/BP≥140/80mmHg in pt≥65y old) were assigned to the extemporaneous combination of NEB5mg and RAM2.5mg. V3 W4: After 4 Weeks ± 2 days controlled pt (BP<130/80mmHg in pt<65y old/ BP<140/80mmHg in pt ≥65y old) continued the same combination of V2 while for pt with uncontrolled BP the RAM dose was up-titrated to 5mg and the pt received the combination NEB/RAM 5/5mg for next 4 weeks. V4 W8: After 4 Weeks ± 2 days controlled pt continued the same combination of V3 for next 4 weeks ± 2 days till V5 (W12). Pt with uncontrolled BP: on NEB/RAM 5/2.5mg were up-titrated to NEB/RAM 5/5mg; on NEB/RAM 5/5mg were up-titrated to NEB/RAM 5/10mg for next 4 weeks ± 2 days till V5. To correctly evaluate additional effect of the combination therapy, the number of pts with uncontrolled BP needed to be balanced at V2 (max 5% difference). Weekly evaluations were performed to maintain a 1:1 during period 2.

    Reporting group values
    Combination Therapy Neb 5mg/ Ram 2.5 or 5 or 10 mg Total
    Number of subjects
    255 255
    Age categorical
    Units: Subjects
        In utero
    0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0
        Newborns (0-27 days)
    0 0
        Infants and toddlers (28 days-23 months)
    0 0
        Children (2-11 years)
    0 0
        Adolescents (12-17 years)
    0 0
        Adults (18-64 years)
    195 195
        From 65-84 years
    60 60
        85 years and over
    0 0
        Not recorded
    0 0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    55.1 ( 12.77 ) -
    Gender categorical
    Units: Subjects
        Female
    133 133
        Male
    122 122

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Nebivolol 5 mg
    Reporting group description
    Eligible patients entered a 4 week run-in period on the same day of the screening visit (Visit 1, Week -4). Patients previously receiving Neb 5 mg continued the same treatment, while patients receiving any other BBs were switched to Neb 5 mg

    Reporting group title
    Ramipril 5 mg
    Reporting group description
    Eligible patients entered a 4 week run-in period on the same day of the screening visit (Visit 1, Week -4). Patients previously receiving RAM 5 mg continued the same treatment, while patients receiving any other ACE-i were switched to RAM 5 mg
    Reporting group title
    Combination Therapy Neb 5mg/ Ram 2.5 or 5 or 10 mg
    Reporting group description
    Visit2 (V2) Week0 (W0): Patients (pts) having uncontrolled BP (BP≥130/80mmHg in pt<65y old/BP≥140/80mmHg in pt≥65y old) were assigned to the extemporaneous combination of NEB5mg and RAM2.5mg. V3 W4: After 4 Weeks ± 2 days controlled pt (BP<130/80mmHg in pt<65y old/ BP<140/80mmHg in pt ≥65y old) continued the same combination of V2 while for pt with uncontrolled BP the RAM dose was up-titrated to 5mg and the pt received the combination NEB/RAM 5/5mg for next 4 weeks. V4 W8: After 4 Weeks ± 2 days controlled pt continued the same combination of V3 for next 4 weeks ± 2 days till V5 (W12). Pt with uncontrolled BP: on NEB/RAM 5/2.5mg were up-titrated to NEB/RAM 5/5mg; on NEB/RAM 5/5mg were up-titrated to NEB/RAM 5/10mg for next 4 weeks ± 2 days till V5. To correctly evaluate additional effect of the combination therapy, the number of pts with uncontrolled BP needed to be balanced at V2 (max 5% difference). Weekly evaluations were performed to maintain a 1:1 during period 2.

    Subject analysis set title
    Efficacy Population
    Subject analysis set type
    Modified intention-to-treat
    Subject analysis set description
    All study participants who signed informed consent, met all screening criteria, were enrolled and received at least one dose of the assigned treatment during run-in period, completed the 4-week run-in period and met criteria at Visit 2 (Week 0) [uncontrolled BP (sitting BP ≥ 130/80 mmHg in patients < 65 years old/sitting BP ≥ 140/80 mmHg in patients ≥ 65 years old) at Visit 2, with adequate treatment adherence (ranging between 80% to 120%)], tolerated treatment, had treatment adherence between 80 – 120 %, had at least one dose of combination therapy and had at least baseline [Visit 2 (Week 0)] and Visit 5 (Week 12) assessments with primary efficacy data. 239 pts were included in Modified intention to treat (mITT) for primary efficacy analysis.

    Primary: Change in mean sitting SBP

    Close Top of page
    End point title
    Change in mean sitting SBP
    End point description
    End point type
    Primary
    End point timeframe
    12 weeks of combination therapy treatment. From study Visit 2 (Week 0) to study Visit 5 (Week 12)
    End point values
    Combination Therapy Neb 5mg/ Ram 2.5 or 5 or 10 mg Efficacy Population
    Number of subjects analysed
    239
    239
    Units: mmHG
        arithmetic mean (standard deviation)
    -19.2 ( 8.62 )
    -19.2 ( 8.62 )
    Statistical analysis title
    SBP at Visit 2 (Week 0) vs Visit 5 (Week 12)
    Statistical analysis description
    Change from Baseline in the Systolic Blood Pressure (SBP). Primary endpoint, verified on the single cohort of patients who completed the run-in period, is calculated as the mean difference in sitting SBP between V2 (W0, Baseline) and V5 (W12, End of Study Visit). This is not a comparison of two different arms, but a comparison of two measurements taken from the same patient treated with combination therapy (single arm paired pre- vs. post-combination therapy comparison)
    Comparison groups
    Combination Therapy Neb 5mg/ Ram 2.5 or 5 or 10 mg v Efficacy Population
    Number of subjects included in analysis
    478
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    < 0.001
    Method
    Wilcoxon
    Parameter type
    Signed Rank Test
    Confidence interval

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From Informed Consent signed to final visit
    Adverse event reporting additional description
    Safety population: Patients who are in the Enrolled population and receive at least 1 dose of monotherapy (either followed by combination therapy or not). For the purpose of safety analyses concerning the combination therapy period, 255, 170, and 71 patients were exposed to at least 1 dose of the NEB/RAM 5/2.5 mg,5 mg,10 mg, respectively.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    26.1
    Reporting groups
    Reporting group title
    Monotherapy
    Reporting group description
    Safety Population that received Monotherapy

    Reporting group title
    Combination therapy Neb5mg/RAM2.5mg
    Reporting group description
    Safety Population that received Combination therapy Neb5mg/RAM2.5mg (the actual number of patients who received NEB 5 mg/RAM 2.5 mg for the entire combination period, patients who were up-titrated to NEB 5 mg/RAM 5 mg at Visit 3 (Week 4) and who were up-titrated to NEB 5 mg/RAM 5 mg or NEB 5 mg/RAM 10 mg at Visit 4 (Week 8), respectively).

    Reporting group title
    Combination therapy Neb5mg/RAM5mg
    Reporting group description
    Safety Population that received Combination therapy Neb5mg/RAM5mg (the actual number of patients who were up-titrated to NEB 5 mg/RAM 5 mg at Visit 3 (Week 4) and who were up-titrated to NEB 5 mg/RAM 5 mg or NEB 5 mg/RAM 10 mg at Visit 4 (Week 8), respectively).

    Reporting group title
    Combination therapy Neb5mg/RAM10mg
    Reporting group description
    Safety Population that received Combination therapy Neb5mg/RAM10mg (the actual number of patients who were up-titrated to NEB 5 mg/RAM 10 mg at Visit 4 (Week 8)).

    Serious adverse events
    Monotherapy Combination therapy Neb5mg/RAM2.5mg Combination therapy Neb5mg/RAM5mg Combination therapy Neb5mg/RAM10mg
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 266 (0.00%)
    0 / 255 (0.00%)
    1 / 170 (0.59%)
    0 / 71 (0.00%)
         number of deaths (all causes)
    0
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    0
    Cardiac disorders
    Arteriospasm coronary
         subjects affected / exposed
    0 / 266 (0.00%)
    0 / 255 (0.00%)
    1 / 170 (0.59%)
    0 / 71 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    Monotherapy Combination therapy Neb5mg/RAM2.5mg Combination therapy Neb5mg/RAM5mg Combination therapy Neb5mg/RAM10mg
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    0 / 266 (0.00%)
    14 / 255 (5.49%)
    18 / 170 (10.59%)
    6 / 71 (8.45%)
    Investigations
    SARS-CoV-2 test positive
         subjects affected / exposed
    0 / 266 (0.00%)
    0 / 255 (0.00%)
    0 / 170 (0.00%)
    1 / 71 (1.41%)
         occurrences all number
    0
    0
    0
    1
    Vascular disorders
    Hypotension
         subjects affected / exposed
    0 / 266 (0.00%)
    1 / 255 (0.39%)
    0 / 170 (0.00%)
    0 / 71 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Nervous system disorders
    Headache
         subjects affected / exposed
    0 / 266 (0.00%)
    0 / 255 (0.00%)
    5 / 170 (2.94%)
    1 / 71 (1.41%)
         occurrences all number
    0
    0
    5
    1
    Sciatica
         subjects affected / exposed
    0 / 266 (0.00%)
    0 / 255 (0.00%)
    2 / 170 (1.18%)
    0 / 71 (0.00%)
         occurrences all number
    0
    0
    2
    0
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    0 / 266 (0.00%)
    0 / 255 (0.00%)
    1 / 170 (0.59%)
    0 / 71 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Gastrointestinal disorders
    Dyspepsia
         subjects affected / exposed
    0 / 266 (0.00%)
    1 / 255 (0.39%)
    1 / 170 (0.59%)
    0 / 71 (0.00%)
         occurrences all number
    0
    1
    1
    0
    Gastroesophageal reflux disease
         subjects affected / exposed
    0 / 266 (0.00%)
    1 / 255 (0.39%)
    0 / 170 (0.00%)
    0 / 71 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Nausea
         subjects affected / exposed
    0 / 266 (0.00%)
    0 / 255 (0.00%)
    0 / 170 (0.00%)
    1 / 71 (1.41%)
         occurrences all number
    0
    0
    0
    1
    Respiratory, thoracic and mediastinal disorders
    Oropharyngeal pain
         subjects affected / exposed
    0 / 266 (0.00%)
    1 / 255 (0.39%)
    0 / 170 (0.00%)
    0 / 71 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    0 / 266 (0.00%)
    1 / 255 (0.39%)
    3 / 170 (1.76%)
    0 / 71 (0.00%)
         occurrences all number
    0
    1
    3
    0
    Back pain
         subjects affected / exposed
    0 / 266 (0.00%)
    0 / 255 (0.00%)
    1 / 170 (0.59%)
    0 / 71 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Spinal pain
         subjects affected / exposed
    0 / 266 (0.00%)
    0 / 255 (0.00%)
    1 / 170 (0.59%)
    0 / 71 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Myalgia
         subjects affected / exposed
    0 / 266 (0.00%)
    0 / 255 (0.00%)
    0 / 170 (0.00%)
    1 / 71 (1.41%)
         occurrences all number
    0
    0
    0
    1
    Infections and infestations
    Influenza
         subjects affected / exposed
    0 / 266 (0.00%)
    4 / 255 (1.57%)
    0 / 170 (0.00%)
    0 / 71 (0.00%)
         occurrences all number
    0
    4
    0
    0
    Nasopharyngitis
         subjects affected / exposed
    0 / 266 (0.00%)
    3 / 255 (1.18%)
    3 / 170 (1.76%)
    0 / 71 (0.00%)
         occurrences all number
    0
    3
    3
    0
    Conjunctivitis
         subjects affected / exposed
    0 / 266 (0.00%)
    1 / 255 (0.39%)
    0 / 170 (0.00%)
    0 / 71 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Pharyngitis
         subjects affected / exposed
    0 / 266 (0.00%)
    1 / 255 (0.39%)
    0 / 170 (0.00%)
    0 / 71 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Sinusitis
         subjects affected / exposed
    0 / 266 (0.00%)
    0 / 255 (0.00%)
    1 / 170 (0.59%)
    0 / 71 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Upper respiratory tract infection
         subjects affected / exposed
    0 / 266 (0.00%)
    0 / 255 (0.00%)
    1 / 170 (0.59%)
    0 / 71 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Bronchitis
         subjects affected / exposed
    0 / 266 (0.00%)
    0 / 255 (0.00%)
    0 / 170 (0.00%)
    1 / 71 (1.41%)
         occurrences all number
    0
    0
    0
    1
    COVID-19
         subjects affected / exposed
    0 / 266 (0.00%)
    0 / 255 (0.00%)
    0 / 170 (0.00%)
    1 / 71 (1.41%)
         occurrences all number
    0
    0
    0
    1
    Metabolism and nutrition disorders
    Gout
         subjects affected / exposed
    0 / 266 (0.00%)
    0 / 255 (0.00%)
    1 / 170 (0.59%)
    0 / 71 (0.00%)
         occurrences all number
    0
    0
    1
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    13 Jul 2023
    Affected Section(s): 2,4,5,7,12 Summary of Revisions Made: For the purpose of this study, uncontrolled BP is amended as follows: sitting SBP/DBP: ≥ 130/80 mmHg in patients < 65 years old sitting SBP/DBP: ≥ 140/80 mmHg in patients ≥ 65 years old. The optimal BP goal is modified accordingly, as follows: sitting BP < 130/80 mmHg in patients < 65 years old sitting BP < 140/80 mmHg in patients ≥ 65 years old. Minor editorial and document formatting revisions: 1) In the following sentence “and” has been replaced by “and/or” for further clarification: “Hypertensive patients with Systolic blood pressure (SBP) ranging from ≥ 140 to ≤ 179 mmHg and/or Diastolic blood pressure (DBP) ranging from ≥ 90 to ≤ 109 mmHg on treatment.” 2) The following sentence has been updated as below for following visits by removing the word first dose: “Intake of the dispensed study medication at the site at the end of all other procedures/assessments” • Screening and start of Run-in period (Visit 1, Week −4) • Assessment period (Visit 2, Week 0) • Assessment period (Visit 3, Week 4) • Assessment period (Visit 4, Week 8) Rationale: Thresholds and target BP goals have been amended by age groups according to 2018 ESC/ESH guidelines

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 17:11:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA